Literature DB >> 17641891

Refractory multiple myeloma treated with homoharringtonine: report of two cases.

Xiudi Yang, Chunmei Yang, Keding Shao, Xingnong Ye, Haitao Meng, Yuhong Zhou, Wenbin Qian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17641891     DOI： 10.1007/s00277-007-0331-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  3 in total

1.  Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin.

Authors:  Junya Kuroda; Yuri Kamitsuji; Shinya Kimura; Eishi Ashihara; Eri Kawata; Yoko Nakagawa; Miki Takeuichi; Yoshihide Murotani; Asumi Yokota; Ruriko Tanaka; Michael Andreeff; Masafumi Taniwaki; Taira Maekawa
Journal:  Int J Hematol       Date:  2008-04-17       Impact factor: 2.490

2.  Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway.

Authors:  Ikiru Atsuta; Shiyu Liu; Yasuo Miura; Kentaro Akiyama; Chider Chen; Ying An; Songtao Shi; Fa-Ming Chen
Journal:  Stem Cell Res Ther       Date:  2013       Impact factor: 6.832

3.  Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.

Authors:  Zachary J Walker; Beau M Idler; Lorraine N Davis; Brett M Stevens; Michael J VanWyngarden; Denis Ohlstrom; Shelby C Bearrows; Andrew Hammes; Clayton A Smith; Craig T Jordan; Tomer M Mark; Peter A Forsberg; Daniel W Sherbenou
Journal:  Clin Cancer Res       Date:  2020-10-27       Impact factor: 13.801
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.